Updates are available Correction dated 2025-06-23
Click to view Correction: https://doi.org/10.1038/s41514-025-00246-9
-
Authors
Moaddel, Ruin
Sanehira, Chad
Keyes, Gregory
Cui, Chang-Yi
Ahmadkhaniha, Reza
Candia, Julián
Price, Nathan L.
Eckroth, Sarah
Middleton, Bryce
Khadeer, Mohammed
Mazucanti, Caio H.
McDevitt, Ross A.
Gorospe, Myriam
de Cabo, Rafael
Egan, Josephine M.
Ramsden, Christopher E.
Ferrucci, Luigi
-
Funding
Funding for this research was provided by:
National Institutes of Health (Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297, Z01-AG-000297)
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 29 April 2025
First Online: 30 May 2025
Change Date: 23 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41514-025-00246-9
Competing interests
: The authors declare competing financial interests: R.M, G.K., M.G., C.E.R and L.F. are listed as co-inventors on a patent for Gingerenone A pro-drugs as senotherapeutics and methods of use. They have assigned their rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government.
